|
World Pharma News RSS Channel
Subscribe to World Pharma News by Email
Follow us on: |
Research & Development
Conferences & Events
- Safety Biomarkers in Drug Development Conference to be held in Bratislava, Slovak Republic
- 4th Annual Clinical Site Partnerships in Central & Eastern Europe, to be held in Budapest, Hungary
- Physicians Go Digital Across the Globe - Webinar May 19
- Emerging Superpowers of Clinical Research - Russia, India, China
Sponsored Ads |
Pharmaceutical CompaniesA | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | ZSponsored AdsPharmaceutical RSS NewsAbbott | Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | Eli Lilly | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda | ... European Commission - Pharmaceuticals US Food and Drug Administration Sponsored Ads
PharmaNews.eu, an advanced web based news engine, addressed to the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical news...For further information and advanced RSS channels, please visit http://www.pharmanews.eu PharmaNews.eu / Latest News |
|||||||||||
Financial
Product
- IRESSA (Gefitinib) Receives Marketing Authorisation in Europe
- AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
- Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia
- New biological therapy Ilaris® approved in US
- Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission
Clinical Trials
- Lu AA24530 shows positive results in major depressive disorder phase II study
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer
- Sutent Significantly Improved Progression-Free Survival
- Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Corporate
- Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Bayer files patent infringement lawsuit against Teva
- Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
- Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities
- GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
News Channels


Roche and Meda, an international specialty pharmaceutical company based in Solna (Stockholm), Sweden, have signed an agreement for the sale of four Roche pharmaceutical products to Meda. The world wide product rights for Marcoumar (Anticoagulant), Torem (Loop diuretic), Tilcotil (painful musculoskeletal disorders) and Aurorix (Depression) are being transferred to Meda for a total amount of 120 million Euros.
The transaction is expected to close in late 2008 and is subject to standard closing conditions.














